Company news

Achieve Life Sciences, Inc. news in 2019

Achieve Life Sciences, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option

December 18, 2019

Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering

December 16, 2019

Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program

December 8, 2019

Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program

November 5, 2019

Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study

September 29, 2019

Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

September 12, 2019

Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial

September 4, 2019

Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences

September 3, 2019

Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update

August 7, 2019

Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation

July 22, 2019

Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

June 20, 2019

Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial

June 10, 2019

Achieve Receives $4.2 Million from Exercise of Warrants

June 2, 2019

Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline

May 29, 2019

Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

April 23, 2019

Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

April 1, 2019

Decks in 2019